{"id":1378,"date":"2025-06-18T09:46:58","date_gmt":"2025-06-18T09:46:58","guid":{"rendered":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/?page_id=1378"},"modified":"2025-11-20T11:40:49","modified_gmt":"2025-11-20T11:40:49","slug":"viernes-28-de-noviembre","status":"publish","type":"page","link":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/viernes-28-de-noviembre\/","title":{"rendered":"Viernes, 28 de Noviembre"},"content":{"rendered":"

<\/p>\n

\n
\n
\n
\n

08:00 – 09:00<\/h4>\n<\/div>\n
\n

GECP GENERAL ASSEMBLY<\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

08:15 – 09:15<\/h4>\n<\/div>\n
\n

SESSION VII: OTHER DRIVER MUTATIONS IN LUNG CANCER<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Chairs<\/span><\/td>Dr. Bartomeu Massut\u00ed<\/span>
\n Hospital General Univ. Dr. Balmis, Alicante<\/span>
\n Dr. Teresa Mor\u00e1n<\/span>
\n ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona<\/span><\/td>\n<\/tr>\n
09:00 - 09:15<\/td>New insights in KRAS mutation<\/span>
\n Dr. Miriam Molina-Arcas<\/span>
\n Francis Crick Institute, London (UK)<\/span><\/td>\n<\/tr>\n
09:15 - 09:30<\/td>Resistance pathways to RAS inhibition<\/span>
\n Dr. Rafael Rosell<\/span>
\n Instituto Oncol\u00f3gico Dr Rosell, Barcelona<\/span><\/td>\n<\/tr>\n
09:30 - 09:45<\/td>BRAF mutations: Small changes, big impact<\/span>
\n Dr. Joaquim Bosch<\/span>
\n ICO, Hospital Univ. Dr. Josep Trueta, Girona<\/span><\/td>\n<\/tr>\n
09:45 - 10:00<\/td> HER2: A new frontier in precision oncology<\/span>
\n Dr. Ernest Nadal<\/span>
\n ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona<\/span><\/td>\n<\/tr>\n
10:00 - 10:15<\/td>Fusions in lung cancer<\/span>
\n Dr. Rosario Garc\u00eda Campelo<\/span>
\n Hospital Univ. de A Coru\u00f1a<\/span><\/td>\n<\/tr>\n
10:15 - 10:30<\/td>Discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

10:30 – 11:30<\/h4>\n<\/div>\n
\n

SESSION VIII: PROFFERED POSTER<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t
Chairs<\/span><\/td>Dr. Enric Carcereny<\/span>
\nICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona<\/span>
\nDr. Manuel D\u00f3mine<\/span>
\nHospital Univ. Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid<\/span><\/td>\n<\/tr>\n
Poster 14<\/td>Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy in non-small cell lung cancer<\/span>
\nDr. Marta Molina-Alejandre<\/span>
\nHospital Univ. Puerta de Hierro, Majadahonda, Madrid<\/span><\/td>\n<\/tr>\n
Poster 21<\/td>Liquid Biopsy: The future of surveillance after curative resection of non-small cell lung cancer?<\/span>
\nDr. Eider Azkona<\/span>
\nHospital Univ. de Cruces, Barakaldo<\/span><\/td>\n<\/tr>\n
Poster 35<\/td>Circulating low density neutrophils as a major mechanismof resistance to first line anti-pd1\/pd-l1 immunotherapy in non-small cell lung cancer<\/span>
\nDr. Natalia Castro<\/span>
\nClinica Univ. de Navarra, Pamplona<\/span><\/td>\n<\/tr>\n
Poster 52<\/td>Circulating tumor DNA as a prognostic and dynamic biomarker in unresectable stage III NSCLC<\/span>
\nDr. Nil Navarro<\/span>
\nHospital del Mar, Barcelona<\/span><\/td>\n<\/tr>\n
Poster 61<\/td>KRAS G12C vs. NON-G12C: Divergent immunotherapy outcomes in non-small cell lung cancer<\/span>
\nDr. Cl\u00e0udia Miquel<\/span>
\nHospital del Mar, Barcelona<\/span><\/td>\n<\/tr>\n
Poster 63<\/td>Neoadjuvant chemo-immunotherapy in non-small cell lung cancer: The hidden value of the lung immune prognostic index (LIPI)<\/span>
\nDr. Karla Medina,<\/span>
\nHospital Univ. Ntra. Sra. de Candelaria, Santa Cruz de, Tenerife<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

11:30 – 12:00<\/h4>\n<\/div>\n
\n

Coffee Break<\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

12:00 – 13:15<\/h4>\n<\/div>\n
\n

SESSION IX: NEW DRUGS DEVELOPMENT IN NSCLC LUNG CANCER<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t
Chairs<\/span><\/td>Dr. Antonio Calles<\/span>
\n Hospital General Univ. Gregorio Mara\u00f1\u00f3n, Madrid<\/span>
\n Dr. Xabier Mielgo<\/span>
\n Hospital Univ. Cruces, Baracaldo<\/span><\/td>\n<\/tr>\n
12:00 - 12:15<\/td>Treating resistance mechanisms in oncogenic diseases<\/span>
\n Dr. \u00d3scar Juan-Vidal<\/span>
\n Hospital Univ. y Polit\u00e9cnico La Fe, Valencia<\/span><\/td>\n<\/tr>\n
12:15 - 12:30<\/td> Is the future conjugated? ADCs in lung cancer treatment<\/span>
\n Dr. Francesca Fusco<\/span>
\n IRCCS - Istituto Nazionale Tumori Regina Elena, Rome (Italy)<\/span><\/td>\n<\/tr>\n
12:30 - 12:45<\/td>Bispecific antibodies: BITES\/TRITES<\/span>
\n Dr. Biagio Ricciuti<\/span>
\n Dana-Farber Cancer Institute, Boston (USA)<\/span><\/td>\n<\/tr>\n
12:45 - 13:00<\/td>Other immunotherapy strategies: Vaccines, cellular therapy, oncolytic virus<\/span>
\n Dr. Enriqueta Felip<\/span>
\n Hospital Univ. Vall d'Hebron, Barcelona<\/span><\/td>\n<\/tr>\n
13:00 - 13:15<\/td>Discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

13:15 – 14:40<\/h4>\n<\/div>\n
\n

Lunch<\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

13:15 – 14:40<\/h4>\n<\/div>\n
\n

LUNCH SATELLITE SYMPOSIUM<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t
Sponsored by Pierre Fabre<\/span><\/td>From gene to clinical decision: Current approaches in BRAF-mutated lung cancer<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

14:40 – 15:55<\/h4>\n<\/div>\n
\n

SESSION X: SCLC, NEUROENDOCRINE AND MESOTHELIOMA<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t
Chairs<\/span><\/td>Dr. Manuel D\u00f3mine<\/span>
\n Hospital Univ. Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid<\/span>
\n Dr. Mar\u00eda \u00c1ngeles Sala<\/span>
\n Hospital Univ. Basurto, Bilbao<\/span><\/td>\n<\/tr>\n
14:40 - 14:55<\/td>Changing landscape in SCLC limited disease<\/span>
\n Dr. Anna Estival<\/span>
\n Hospital Univ. Insular de Gran Canaria, Las Palmas<\/span><\/td>\n<\/tr>\n
14:55 - 15:10<\/td>New strategies in SCLC metastatic disease<\/span>
\n Dr. Edurne Arriola<\/span>
\n Hospital del Mar, Barcelona<\/span><\/td>\n<\/tr>\n
15:10 - 15:25<\/td>Large cell neuroendocrine new insights<\/span>
\n Dr. Noem\u00ed Reguart<\/span>
\n Hospital Cl\u00ednic Barcelona<\/span><\/td>\n<\/tr>\n
15:25 - 15:40<\/td>Systemic treatment in mesothelioma<\/span>
\n Dr. Bartomeu Massut\u00ed<\/span>
\n Hospital General Univ. Dr. Balmis, Alicante<\/span><\/td>\n<\/tr>\n
15:40 - 15:55<\/td>Discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

15:55 – 17:10<\/h4>\n<\/div>\n
\n

SESSION XI: IMMUNOTHERAPY<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t
Chairs<\/span><\/td>Dr. Javier de Castro<\/span>
\n Hospital Univ. La Paz, Madrid<\/span>
\n Dr. Delvys Rodr\u00edguez-Abreu<\/span>
\n Hospital Univ. Insular de Gran Canaria, Las Palmas<\/span><\/td>\n<\/tr>\n
15:55 - 16:10<\/td>How to choose immunotherapy agent\/s in first line<\/span>
\n Dr. Mart\u00edn L\u00e1zaro<\/span>
\n Complejo Hospitalario Univ. de Vigo<\/span><\/td>\n<\/tr>\n
16:10 - 16:25<\/td>Microbiota role in immunotherapy efficacy<\/span>
\n Dr. Laurence Zitvogel<\/span>
\n Institut Gustave-Roussy, Villejuif (France)<\/span><\/td>\n<\/tr>\n
16:25 - 16:40<\/td>Optimization of IO treatment: Administration schedule, circadian rhythms...<\/span>
\n Dr. Sergio V\u00e1zquez<\/span>
\n Hospital Univ. Lucus Augusti, Lugo<\/span><\/td>\n<\/tr>\n
16:40 - 16:55<\/td> Consolidation RT in metastatic disease without oncogenic driver<\/span>
\n Dr. Amelia Insa<\/span>
\n Hospital Cl\u00ednico Univ. de Valencia<\/span><\/td>\n<\/tr>\n
16:55 - 17:10<\/td>Discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

17:10 – 17:25<\/h4>\n<\/div>\n
\n

Closing Remarks<\/h4>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

08:00 – 09:00 GECP GENERAL ASSEMBLY 08:15 – 09:15 SESSION VII: OTHER DRIVER MUTATIONS IN LUNG CANCER 10:30 – 11:30 SESSION VIII: PROFFERED POSTER 11:30 – 12:00 Coffee Break 12:00 – 13:15 SESSION IX: NEW DRUGS DEVELOPMENT IN NSCLC LUNG CANCER 13:15 – 14:40 Lunch 13:15 – 14:40 LUNCH SATELLITE SYMPOSIUM 14:40 – 15:55 SESSION […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1378","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/pages\/1378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/comments?post=1378"}],"version-history":[{"count":7,"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/pages\/1378\/revisions"}],"predecessor-version":[{"id":1546,"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/pages\/1378\/revisions\/1546"}],"wp:attachment":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/lungcancer2025\/wp-json\/wp\/v2\/media?parent=1378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}